Clinical Trials Logo

Filter by:
NCT ID: NCT05173441 Not yet recruiting - COVID-19 Clinical Trials

Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients

Start date: December 30, 2021
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19.

NCT ID: NCT05169333 Recruiting - Clinical trials for Cardiovascular Diseases

The Oxford Risk Factors And Non-Invasive Imaging Study

ORFAN
Start date: February 23, 2016
Phase:
Study type: Observational [Patient Registry]

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

NCT ID: NCT05168384 Not yet recruiting - Multiple Sclerosis Clinical Trials

Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

PHOMS
Start date: December 2021
Phase: Phase 1/Phase 2
Study type: Interventional

PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS). The primary objective is the safety profile assessment of the investigational intervention (Extracorporeal Photopheresis -ECP) and its preliminary efficacy evaluation, while the secondary objective is the assessment of the immune response profile in MS patients.

NCT ID: NCT05144178 Recruiting - Clinical trials for COVID-19 Respiratory Infection

Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )

EHS-Strategy
Start date: November 14, 2021
Phase:
Study type: Observational

Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions. The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. As the clinical trial results are too preliminary for the drug to enter routine use in UAE the drug approved only for emergency use, until further evidence shows Sotrovimab is effective, so we thought about this study as a tool to assess the success of Emirats Health service (EHS) strategy for fighting against COVID-19 outside the hospital setting.

NCT ID: NCT05140798 Recruiting - Clinical trials for Bariatric Surgery Candidate

Abu Dhabi Diabetes and Obesity Study -2 Bariatric

ADOS-2B
Start date: April 25, 2016
Phase:
Study type: Observational [Patient Registry]

Study on outcomes on bariatric surgery, particularly in terms of metabolic parameters in the UAE is scant. Also Genetic data from this population is limited and hence a study on genetic determinants of response to bariatric surgery is highly warranted. This study is expected to provide a better understanding of the causes of severe obesity in the UAE population and help us to evaluate the efficacy of Bariatric surgery in patients with genetic forms of obesity. The information generated will allow us to better advise patients regarding the risks and benefits of Bariatric Surgery as a treatment. Objective To investigate the metabolic outcomes of bariatric surgery, to study the prevalence of monogenic forms of obesity among a cohort of patients with morbid obesity who underwent bariatric surgery and to compare the outcomes of Bariatric surgery in patients with and without underlying genetic condition.

NCT ID: NCT05126966 Not yet recruiting - Clinical trials for Neovascular Age-Related Macular Degeneration

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Diagrid
Start date: March 24, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the Port Delivery System with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per treat-and-extend (aflibercept T&E) in subjects with neovascular (wet) age-related macular degeneration (nAMD).

NCT ID: NCT05076981 Recruiting - Infertility, Female Clinical Trials

Progesterone Levels During Ovulation and Luteal Phase

Start date: September 23, 2021
Phase:
Study type: Observational

Natural cycles are evaluated during fertility treatments for different therapeutic options, like insemination (IUI), time intercourse (TI) or frozen-thawed embryo transfers (FET). Two possible protocols can be used for natural cycles, with or without hCG trigger. Usually, studies including natural cycles consider both options as equivalent, not considering the possible bias that the exogenous hCG (human chorionic gonadotrophin) might have. In this prospective study, Investigators aim to evaluate the differences in the hormonal profile during the ovulation when it occurs spontaneously vs triggered with a bolus of hCG.

NCT ID: NCT05069129 Recruiting - COVID-19 Pneumonia Clinical Trials

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Start date: October 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 4-6 months, 7-9 months and >9 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.

NCT ID: NCT05045053 Recruiting - Corneal Disease Clinical Trials

Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

dry eye disease after corneal collagen cross linking affect ocular function leading to reduced vision, photophobia, glare, halos, and foreign body sensation.

NCT ID: NCT05043311 Recruiting - COVID-19 Clinical Trials

The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.